Compare United States Brent Oil Fund LP (BNO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Brent Oil Fund LP vs Zimmer Biomet Holdings Inc — how do they compare? United States Brent Oil Fund LP trades at $46.45, while Zimmer Biomet Holdings Inc trades at $91.55 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc pays a 1.05% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BNO | ZBH | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $60.13 | $107.71 |
52-Week Low | $27.20 | $79.58 |
Market Cap | — | $17.61B |
Enterprise Value | — | $24.66B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNO, a US-listed oil-focused stock, trades at $46.00, up 9.13% on the day, driven by escalating Middle East tensions that have pushed crude prices to one-month highs. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 86 suggests overbought conditions. Recent news highlights supply risks from U.S.-Iran hostilities, including blockades and strikes, which are boosting energy sector sentiment and driving volatility.
The outlook for BNO remains heavily tied to geopolitical developments and oil price momentum. Upside potential exists if supply disruptions persist, but risks include rapid de-escalation or demand weakness. Investors should weigh the stock's sensitivity to crude fluctuations against current bullish technical and sentiment signals.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Brent Oil Fund LP
BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.
Read more on BNO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
